A股異動 | 智飛生物升超6% 擬收購宸安生物100%股權 版圖延伸至糖尿病等疾病領域
智飛生物(300122.SZ)升超6%,報69.24元,股價創逾9個月新高,總市值1662億元。智飛生物昨日晚間公吿,公司擬以現金收購重慶智睿投資有限公司(簡稱“智睿投資”)、張高峽持有的重慶宸安生物製藥有限公司(下稱“宸安生物”)100%股權並簽署股權收購意向性協議。公吿稱,本次交易完成後,宸安生物將成為公司的全資子公司。公司業務版圖延伸覆蓋至糖尿病、肥胖等代謝類疾病領域,並以宸安生物為主體拓展進入治療類生物製藥領域。宸安生物為智飛生物實際控制人蔣仁生所控制的企業,因此該事項構成關聯交易。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.